An update on PARP inhibitors—moving to the adjuvant setting

@article{Sonnenblick2015AnUO,
  title={An update on PARP inhibitors—moving to the adjuvant setting},
  author={Amir Sonnenblick and Evandro de Azambuja and Hatem A. Azim and Martine J. Piccart},
  journal={Nature Reviews Clinical Oncology},
  year={2015},
  volume={12},
  pages={27-41}
}
Inhibition of poly(ADP-ribose) polymerase (PARP) enzymes is a potential synthetic lethal therapeutic strategy in cancers harbouring specific DNA-repair defects, including those arising in carriers of BRCA1 or BRCA2 mutations. Since the development of first-generation PARP inhibitors more than a decade ago, numerous clinical trials have been performed to… CONTINUE READING